Bioequivalence Studies of New Generic Formulations of Vildagliptin and Fixed-Drug Combination of Vildagliptin and Metformin Versus Respective Originator Products in ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2022-05-11

AUTHORS

Yvonne Schnaars, Sumedh Gaikwad, Ulrike Gottwald-Hostalek, Ulrike Klingberg, Hari Kiran Chary Vadla, Vamshi Ramana Prathap

ABSTRACT

IntroductionVildagliptin and metformin are two well-established oral antidiabetics with a complementary mechanism of action. Two new generic products, vildagliptin and its fixed-drug combination (FDC) with metformin, were tested for bioequivalence versus the approved originator reference products (Galvus® and Eucreas®).MethodsThree randomized studies with two-treatment, two-period, two-sequence crossover design were conducted in healthy adults. One study evaluated vildagliptin 50 mg tablets as single dose under fasting conditions. Vildagliptin–metformin FDC tablet strengths of 50/850 mg and 50/1000 mg were evaluated in separate studies as single dose under fed conditions, given 30 min after a standardized high-fat, high-calorie breakfast following 10 h overnight fasting. Blood samples for analysis were collected until 24 h after dosing in each study period. Bioequivalence between test (T) and reference (R) products required 90% confidence interval (CIs) for the geometric least square (LS) mean T/R ratio to be within 80–125% for the pharmacokinetic parameters, maximum plasma concentration (Cmax), and area under the curve (AUC0–t).ResultsThe 90% CIs of geometric LS means of T/R ratio for Cmax and AUC0–t with vildagliptin tablets of 50 mg were 92.22–103.94% and 99.00–102.66%, respectively; corresponding results with FDC tablets for 50/850 mg tablets were 94.81–115.41% and 95.28–106.00% for vildagliptin and 90.87–101.18% and 90.56–100.09% for metformin; for 50/1000 mg tablets Cmax and AUC0–t were 105.56–122.30% and 98.30–107.55%, respectively, for vildagliptin and 92.14–103.73% and 94.60–101.81%, respectively, for metformin. Other parameters such as AUC0–∞, time to maximum concentration (Tmax), and terminal half-life (t1/2) were comparable between test and reference products. Adverse events (AEs), mainly vomiting, were reported without relevant difference between test and reference products in each study. AEs were generally mild and transient. No severe or serious AEs occurred.ConclusionsThe new generic drug products of vildagliptin and the FDCs of vildagliptin and metformin demonstrated bioequivalence to the approved originator products and are therefore expected to provide similar therapeutic effects. More... »

PAGES

1215-1229

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-022-01269-1

DOI

http://dx.doi.org/10.1007/s13300-022-01269-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1147780832

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35543870


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Merck KGaA, Frankfurter Str. 250, Post code F131 /001, 64293, Darmstadt, Germany", 
          "id": "http://www.grid.ac/institutes/grid.39009.33", 
          "name": [
            "Merck KGaA, Frankfurter Str. 250, Post code F131 /001, 64293, Darmstadt, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schnaars", 
        "givenName": "Yvonne", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Merck KGaA, Frankfurter Str. 250, Post code F131 /001, 64293, Darmstadt, Germany", 
          "id": "http://www.grid.ac/institutes/grid.39009.33", 
          "name": [
            "Merck KGaA, Frankfurter Str. 250, Post code F131 /001, 64293, Darmstadt, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gaikwad", 
        "givenName": "Sumedh", 
        "id": "sg:person.016467376453.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016467376453.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Merck KGaA, Frankfurter Str. 250, Post code F131 /001, 64293, Darmstadt, Germany", 
          "id": "http://www.grid.ac/institutes/grid.39009.33", 
          "name": [
            "Merck KGaA, Frankfurter Str. 250, Post code F131 /001, 64293, Darmstadt, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gottwald-Hostalek", 
        "givenName": "Ulrike", 
        "id": "sg:person.0706511421.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706511421.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Alfred E. Tiefenbacher GmbH & Co KG, Hamburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.508924.2", 
          "name": [
            "Alfred E. Tiefenbacher GmbH & Co KG, Hamburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Klingberg", 
        "givenName": "Ulrike", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AET Laboratories Private Limited, Hyderabad, India", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "AET Laboratories Private Limited, Hyderabad, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vadla", 
        "givenName": "Hari Kiran Chary", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AET Laboratories Private Limited, Hyderabad, India", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "AET Laboratories Private Limited, Hyderabad, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Prathap", 
        "givenName": "Vamshi Ramana", 
        "id": "sg:person.015123107220.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015123107220.08"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00125-018-4729-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107409514", 
          "https://doi.org/10.1007/s00125-018-4729-5"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-05-11", 
    "datePublishedReg": "2022-05-11", 
    "description": "IntroductionVildagliptin and metformin are two well-established oral antidiabetics with a complementary mechanism of action. Two new generic products, vildagliptin and its fixed-drug combination (FDC) with metformin, were tested for bioequivalence versus the approved originator reference products (Galvus\u00ae and Eucreas\u00ae).MethodsThree randomized studies with two-treatment, two-period, two-sequence crossover design were conducted in healthy adults. One study evaluated vildagliptin 50\u00a0mg tablets as single dose under fasting conditions. Vildagliptin\u2013metformin FDC tablet strengths of 50/850\u00a0mg and 50/1000\u00a0mg were evaluated in separate studies as single dose under fed conditions, given 30\u00a0min after a standardized high-fat, high-calorie breakfast following 10\u00a0h overnight fasting. Blood samples for analysis were collected until 24\u00a0h after dosing in each study period. Bioequivalence between test (T) and reference (R) products required 90% confidence interval (CIs) for the geometric least square\u00a0(LS) mean T/R ratio to be within 80\u2013125% for the pharmacokinetic parameters, maximum plasma concentration (Cmax), and area under the curve (AUC0\u2013t).ResultsThe 90%\u00a0CIs of geometric LS means of T/R ratio for Cmax and AUC0\u2013t with vildagliptin tablets of 50\u00a0mg were 92.22\u2013103.94% and 99.00\u2013102.66%, respectively; corresponding results with FDC tablets for 50/850\u00a0mg tablets were 94.81\u2013115.41% and 95.28\u2013106.00% for vildagliptin and 90.87\u2013101.18% and 90.56\u2013100.09% for metformin; for 50/1000\u00a0mg tablets Cmax and AUC0\u2013t were 105.56\u2013122.30% and 98.30\u2013107.55%, respectively, for vildagliptin and 92.14\u2013103.73% and 94.60\u2013101.81%, respectively, for metformin. Other parameters such as AUC0\u2013\u221e, time to maximum concentration (Tmax), and terminal half-life (t1/2) were comparable between test and reference products. Adverse events (AEs), mainly vomiting, were reported without relevant difference between test and reference products in each study. AEs were generally mild and transient. No severe or serious AEs occurred.ConclusionsThe new generic drug products of vildagliptin and the FDCs of vildagliptin and metformin demonstrated bioequivalence to the approved originator products and are therefore expected to provide similar therapeutic effects.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13300-022-01269-1", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "13"
      }
    ], 
    "keywords": [
      "fixed-drug combinations", 
      "geometric least squares", 
      "adverse events", 
      "single dose", 
      "confidence intervals", 
      "high-calorie breakfast", 
      "reference product", 
      "serious adverse events", 
      "two-sequence crossover design", 
      "maximum plasma concentration", 
      "similar therapeutic effects", 
      "new generic formulation", 
      "originator product", 
      "vildagliptin 50", 
      "oral antidiabetics", 
      "FDC tablet", 
      "plasma concentrations", 
      "therapeutic effect", 
      "healthy volunteers", 
      "blood samples", 
      "new generic product", 
      "pharmacokinetic parameters", 
      "crossover design", 
      "originator reference product", 
      "healthy adults", 
      "metformin", 
      "two-treatment", 
      "vildagliptin", 
      "study period", 
      "AUC0", 
      "fed conditions", 
      "generic drug products", 
      "two-period", 
      "bioequivalence", 
      "Cmax", 
      "relevant differences", 
      "dose", 
      "bioequivalence study", 
      "generic formulation", 
      "separate studies", 
      "complementary mechanisms", 
      "generic products", 
      "tablets", 
      "maximum concentration", 
      "study", 
      "antidiabetics", 
      "breakfast", 
      "drug products", 
      "volunteers", 
      "adults", 
      "test", 
      "MethodsThree", 
      "concentration", 
      "min", 
      "interval", 
      "combination", 
      "R ratio", 
      "period", 
      "differences", 
      "tablet strength", 
      "action", 
      "ratio", 
      "events", 
      "effect", 
      "mechanism", 
      "new generic drug products", 
      "samples", 
      "conditions", 
      "time", 
      "products", 
      "curves", 
      "analysis", 
      "area", 
      "results", 
      "parameters", 
      "formulation", 
      "design", 
      "strength", 
      "least squares", 
      "corresponding results", 
      "squares"
    ], 
    "name": "Bioequivalence Studies of New Generic Formulations of Vildagliptin and Fixed-Drug Combination of Vildagliptin and Metformin Versus Respective Originator Products in Healthy Volunteers", 
    "pagination": "1215-1229", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1147780832"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-022-01269-1"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35543870"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-022-01269-1", 
      "https://app.dimensions.ai/details/publication/pub.1147780832"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T17:12", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_942.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13300-022-01269-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01269-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01269-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01269-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01269-1'


 

This table displays all metadata directly associated to this object as RDF triples.

184 TRIPLES      21 PREDICATES      107 URIs      98 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-022-01269-1 schema:about anzsrc-for:11
2 anzsrc-for:1115
3 schema:author N279becc110244dae9677c7eb90775da1
4 schema:citation sg:pub.10.1007/s00125-018-4729-5
5 schema:datePublished 2022-05-11
6 schema:datePublishedReg 2022-05-11
7 schema:description IntroductionVildagliptin and metformin are two well-established oral antidiabetics with a complementary mechanism of action. Two new generic products, vildagliptin and its fixed-drug combination (FDC) with metformin, were tested for bioequivalence versus the approved originator reference products (Galvus® and Eucreas®).MethodsThree randomized studies with two-treatment, two-period, two-sequence crossover design were conducted in healthy adults. One study evaluated vildagliptin 50 mg tablets as single dose under fasting conditions. Vildagliptin–metformin FDC tablet strengths of 50/850 mg and 50/1000 mg were evaluated in separate studies as single dose under fed conditions, given 30 min after a standardized high-fat, high-calorie breakfast following 10 h overnight fasting. Blood samples for analysis were collected until 24 h after dosing in each study period. Bioequivalence between test (T) and reference (R) products required 90% confidence interval (CIs) for the geometric least square (LS) mean T/R ratio to be within 80–125% for the pharmacokinetic parameters, maximum plasma concentration (Cmax), and area under the curve (AUC0–t).ResultsThe 90% CIs of geometric LS means of T/R ratio for Cmax and AUC0–t with vildagliptin tablets of 50 mg were 92.22–103.94% and 99.00–102.66%, respectively; corresponding results with FDC tablets for 50/850 mg tablets were 94.81–115.41% and 95.28–106.00% for vildagliptin and 90.87–101.18% and 90.56–100.09% for metformin; for 50/1000 mg tablets Cmax and AUC0–t were 105.56–122.30% and 98.30–107.55%, respectively, for vildagliptin and 92.14–103.73% and 94.60–101.81%, respectively, for metformin. Other parameters such as AUC0–∞, time to maximum concentration (Tmax), and terminal half-life (t1/2) were comparable between test and reference products. Adverse events (AEs), mainly vomiting, were reported without relevant difference between test and reference products in each study. AEs were generally mild and transient. No severe or serious AEs occurred.ConclusionsThe new generic drug products of vildagliptin and the FDCs of vildagliptin and metformin demonstrated bioequivalence to the approved originator products and are therefore expected to provide similar therapeutic effects.
8 schema:genre article
9 schema:isAccessibleForFree true
10 schema:isPartOf N749380f0c00842e7807415c6ef310b3f
11 Nc6fa450c18a8459cbb22e52c8bb97c4f
12 sg:journal.1044057
13 schema:keywords AUC0
14 Cmax
15 FDC tablet
16 MethodsThree
17 R ratio
18 action
19 adults
20 adverse events
21 analysis
22 antidiabetics
23 area
24 bioequivalence
25 bioequivalence study
26 blood samples
27 breakfast
28 combination
29 complementary mechanisms
30 concentration
31 conditions
32 confidence intervals
33 corresponding results
34 crossover design
35 curves
36 design
37 differences
38 dose
39 drug products
40 effect
41 events
42 fed conditions
43 fixed-drug combinations
44 formulation
45 generic drug products
46 generic formulation
47 generic products
48 geometric least squares
49 healthy adults
50 healthy volunteers
51 high-calorie breakfast
52 interval
53 least squares
54 maximum concentration
55 maximum plasma concentration
56 mechanism
57 metformin
58 min
59 new generic drug products
60 new generic formulation
61 new generic product
62 oral antidiabetics
63 originator product
64 originator reference product
65 parameters
66 period
67 pharmacokinetic parameters
68 plasma concentrations
69 products
70 ratio
71 reference product
72 relevant differences
73 results
74 samples
75 separate studies
76 serious adverse events
77 similar therapeutic effects
78 single dose
79 squares
80 strength
81 study
82 study period
83 tablet strength
84 tablets
85 test
86 therapeutic effect
87 time
88 two-period
89 two-sequence crossover design
90 two-treatment
91 vildagliptin
92 vildagliptin 50
93 volunteers
94 schema:name Bioequivalence Studies of New Generic Formulations of Vildagliptin and Fixed-Drug Combination of Vildagliptin and Metformin Versus Respective Originator Products in Healthy Volunteers
95 schema:pagination 1215-1229
96 schema:productId N777f789f093e4b4bb208cb1f856b2751
97 N9962abf01daa4345873f4b3e16d4ece8
98 Nd643d4140fe042db86a3b3f16284fa02
99 schema:sameAs https://app.dimensions.ai/details/publication/pub.1147780832
100 https://doi.org/10.1007/s13300-022-01269-1
101 schema:sdDatePublished 2022-08-04T17:12
102 schema:sdLicense https://scigraph.springernature.com/explorer/license/
103 schema:sdPublisher N436531a315fc41f191e33bfed06ec18f
104 schema:url https://doi.org/10.1007/s13300-022-01269-1
105 sgo:license sg:explorer/license/
106 sgo:sdDataset articles
107 rdf:type schema:ScholarlyArticle
108 N025b10c1eced42e4a0d5e31473530c4b schema:affiliation grid-institutes:grid.39009.33
109 schema:familyName Schnaars
110 schema:givenName Yvonne
111 rdf:type schema:Person
112 N0507014b99a6499692266181fdd0842d rdf:first N37dd0fe3d6614114b61375cab82c4ebf
113 rdf:rest N2c6944ffaa2d44049a4dfd77e6bbfdd8
114 N279becc110244dae9677c7eb90775da1 rdf:first N025b10c1eced42e4a0d5e31473530c4b
115 rdf:rest Ne6ccc43b66a94faabe41c6b236682fe4
116 N2c6944ffaa2d44049a4dfd77e6bbfdd8 rdf:first N81dfa4b2778740f198b7484efe639a6d
117 rdf:rest N569c02896bc8486ca05ef54446d01e35
118 N37dd0fe3d6614114b61375cab82c4ebf schema:affiliation grid-institutes:grid.508924.2
119 schema:familyName Klingberg
120 schema:givenName Ulrike
121 rdf:type schema:Person
122 N436531a315fc41f191e33bfed06ec18f schema:name Springer Nature - SN SciGraph project
123 rdf:type schema:Organization
124 N569c02896bc8486ca05ef54446d01e35 rdf:first sg:person.015123107220.08
125 rdf:rest rdf:nil
126 N749380f0c00842e7807415c6ef310b3f schema:issueNumber 6
127 rdf:type schema:PublicationIssue
128 N777f789f093e4b4bb208cb1f856b2751 schema:name dimensions_id
129 schema:value pub.1147780832
130 rdf:type schema:PropertyValue
131 N81dfa4b2778740f198b7484efe639a6d schema:affiliation grid-institutes:None
132 schema:familyName Vadla
133 schema:givenName Hari Kiran Chary
134 rdf:type schema:Person
135 N9962abf01daa4345873f4b3e16d4ece8 schema:name pubmed_id
136 schema:value 35543870
137 rdf:type schema:PropertyValue
138 Nc6fa450c18a8459cbb22e52c8bb97c4f schema:volumeNumber 13
139 rdf:type schema:PublicationVolume
140 Nd3a3c6f19e0145fe90f6747f2cfe092a rdf:first sg:person.0706511421.33
141 rdf:rest N0507014b99a6499692266181fdd0842d
142 Nd643d4140fe042db86a3b3f16284fa02 schema:name doi
143 schema:value 10.1007/s13300-022-01269-1
144 rdf:type schema:PropertyValue
145 Ne6ccc43b66a94faabe41c6b236682fe4 rdf:first sg:person.016467376453.72
146 rdf:rest Nd3a3c6f19e0145fe90f6747f2cfe092a
147 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
148 schema:name Medical and Health Sciences
149 rdf:type schema:DefinedTerm
150 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
151 schema:name Pharmacology and Pharmaceutical Sciences
152 rdf:type schema:DefinedTerm
153 sg:journal.1044057 schema:issn 1869-6953
154 1869-6961
155 schema:name Diabetes Therapy
156 schema:publisher Springer Nature
157 rdf:type schema:Periodical
158 sg:person.015123107220.08 schema:affiliation grid-institutes:None
159 schema:familyName Prathap
160 schema:givenName Vamshi Ramana
161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015123107220.08
162 rdf:type schema:Person
163 sg:person.016467376453.72 schema:affiliation grid-institutes:grid.39009.33
164 schema:familyName Gaikwad
165 schema:givenName Sumedh
166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016467376453.72
167 rdf:type schema:Person
168 sg:person.0706511421.33 schema:affiliation grid-institutes:grid.39009.33
169 schema:familyName Gottwald-Hostalek
170 schema:givenName Ulrike
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706511421.33
172 rdf:type schema:Person
173 sg:pub.10.1007/s00125-018-4729-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107409514
174 https://doi.org/10.1007/s00125-018-4729-5
175 rdf:type schema:CreativeWork
176 grid-institutes:None schema:alternateName AET Laboratories Private Limited, Hyderabad, India
177 schema:name AET Laboratories Private Limited, Hyderabad, India
178 rdf:type schema:Organization
179 grid-institutes:grid.39009.33 schema:alternateName Merck KGaA, Frankfurter Str. 250, Post code F131 /001, 64293, Darmstadt, Germany
180 schema:name Merck KGaA, Frankfurter Str. 250, Post code F131 /001, 64293, Darmstadt, Germany
181 rdf:type schema:Organization
182 grid-institutes:grid.508924.2 schema:alternateName Alfred E. Tiefenbacher GmbH & Co KG, Hamburg, Germany
183 schema:name Alfred E. Tiefenbacher GmbH & Co KG, Hamburg, Germany
184 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...